ADC Therapeutics Shares Are Trading Higher. The Company Announced the Completion of Dose Escalation in LOTIS-7, a Phase 1b Open-label Clinical Trial Evaluating ZYNLONTA in Combination With Glofitamab or Mosunetuzumab in Heavily Pre-treated Patients With Relapsed/refractory B-cell Non-Hodgkin Lymphoma
ADC Therapeutics的股價正在走高。該公司宣佈完成 LOTIS-7 的劑量遞增，這是一項1b期的開放標籤臨床試驗，評估ZYNLONTA與Glofitamab或Mosunetuzumab聯合治療的復發/難治性B細胞非霍奇金淋巴瘤患者